Gefapixant Under Review for Refractory Chronic Cough – Pulmonology Advisor
The FDA has accepted for review the NDA for gefapixant for refractory or unexplained chronic cough.
Related Articles
Cough Severity May Predict Disease Progression in Fibrotic ILD
Researchers analyzed the relationship between cough severity in fibrotic ILD and patients’ baseline clinical parameters, disease progression, and prognosis.
Who is Most Likely to Quit Asthma Multi-Inhaler Triple Therapy After 6 Months?
Researchers characterized the clinical features, treatment regimens, and demographics of patients with asthma who initiated MITT and subsequently quit vs continued.
Fasenra Approved for Pediatric Patients With Severe Eosinophilic Asthma
Previously, the treatment had only been approved for patients 12 years and older.
Adjuvant Alectinib Improves Disease-Free Survival in Lung Cancer
Findings seen among patients with resected ALK-positive non-small cell lung cancer
SARS-CoV-2 Positivity Not Linked to New Asthma Diagnosis in Children
Black race, food allergies, allergic rhinitis significantly associated with new diagnosis of asthma
CPAP Benefit in CVD With OSA Depends on Hypercholesterolemia, OSA Event Length
Researchers explored the cardiovascular benefit vs harm of prescribing CPAP in patients with acute coronary syndrome and nonsleepy OSA.
Race-Neutral FEV1Q Approach May More Effectively Evaluate Lung Function
Researchers assessed whether the lower boundary of FEV1 varied by race and whether race affected the link between FEV1Q and mortality.
Breathlessness Linked to Overweight, Stress, Cardiac and Respiratory Conditions
Researchers evaluated which medical conditions were associated with breathlessness in a population of middle-aged adults.
PAH Risk Scoring Systems Can Also Predict Survival in Pulmonary Hypertension
Researchers assessed whether risk scores originally developed for PAH had prognostic value for patients in pulmonary hypertension groups 1 to 4.
Rifampicin Flat Dosing and Weight-Banded Dosing Comparable in Patients With TB
Researchers compared the efficacy and safety of rifampicin flat-dosing vs weight-banded dosing in patients with TB.